Chan, Adrienne YL;
Yuen, Andrew SC;
Tsai, Daniel HT;
Lau, Wallis CY;
Jani, Yoghini H;
Hsia, Yingfen;
Osborn, David PJ;
... Man, Kenneth KC; + view all
(2023)
Gabapentinoid consumption in 65 countries and regions from 2008 to 2018: a longitudinal trend study.
Nature Communications
, 14
, Article 5005. 10.1038/s41467-023-40637-8.
Preview |
Text
Man-Gabapentinoid consumption in 65 countries and regions from 2008 to 2018 a longitudinal trend study.pdf Download (1MB) | Preview |
Abstract
Recent studies raised concerns about the increasing use of gabapentinoids in different countries. With their potential for misuse and addiction, understanding the global consumption of gabapentinoids will offer us a platform to examine the need for any interventional policies. This longitudinal trend study utilised pharmaceutical sales data from 65 countries and regions across the world to evaluate the global trends in gabapentinoid consumption between 2008-2018. The multinational average annual percentage change of gabapentinoid consumption was +17.20%, increased from 4.17 defined daily dose per ten thousand inhabitants per day (DDD/TID) in 2008 to 18.26 DDD/TID in 2018. High-income countries had the highest pooled gabapentinoid consumption rate (39.92 DDD/TID) in 2018, which was more than six times higher than the lower-middle income countries (6.11 DDD/TID). The study shows that despite differences in healthcare system and culture, a consistent increase in gabapentinoid consumption is observed worldwide, with high-income countries remaining the largest consumers.
| Type: | Article |
|---|---|
| Title: | Gabapentinoid consumption in 65 countries and regions from 2008 to 2018: a longitudinal trend study |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1038/s41467-023-40637-8 |
| Publisher version: | https://doi.org/10.1038/s41467-023-40637-8 |
| Language: | English |
| Additional information: | Copyright © The Author(s) 2023. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/ licenses/by/4.0/. |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences > UCL School of Pharmacy UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences > UCL School of Pharmacy > Practice and Policy |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10172716 |
Archive Staff Only
 |
View Item |
